Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Predicts Diabetes Mellitus Type 1 Risk

By LabMedica International staff writers
Posted on 04 Jul 2013
Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is equivocal.

Diabetes mellitus type 1 can occur at any age and it starts with the immune system destroying insulin-producing beta cells, which eventually stops the production of insulin and without insulin the body cannot control blood sugar or glucose. More...


Scientists based at the Helmholtz Zentrum (Munich, Germany) gathered data from three different studies, which included a total of 13,377 children. The study involved analyzing blood samples taken from children to identify any preclinical clues that indicate any increased risk of type 1 diabetes. Two diabetes-related autoantibodies were found to be the strongest indicators of diabetes risk.

The children’s genetic risk for type 1 diabetes was estimated by measuring the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, and insulinoma antigen 2 (IA2) autoantibodies. At the 10-year follow-up, an overwhelming 70% of the children with multiple islet autoantibodies developed type 1 diabetes, compared to 15% among those with just one autoantibody.

At follow-up, 8% of the children had one or more of the autoantibodies, indicators for the destruction of insulin, 585 children had at least two autoantibodies and 474 were found to have just one. Nearly half of the children with two or more autoantibodies went on to develop diabetes within five years, and four out of every five of them became diabetic within fifteen years. Only 14.5% of children with just one autoantibody developed type 1 diabetes after 10 years.

The authors concluded that the detection of multiple islet autoantibodies in children who are genetically at risk marks a preclinical stage of type 1 diabetes. Thus, the development of multiple islet autoantibodies in children predicts type 1 diabetes. Future prevention studies should focus on this high-risk population.

"Jay S. Skyler, MD, and Jay M. Sosenko, MD, both from the Leonard M. Miller School of Medicine (Miami, FL, USA) wrote in an accompanying editorial: "If you have two or more autoantibodies, it's nearly inevitable that you will develop the disease. Most people, even physicians, don't appreciate this risk." The study was published on June 19, 2013, in the Journal of the American Medical Association.

Related Links:
Helmholtz Zentrum
Leonard M. Miller School of Medicine



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.